TY - JOUR
T1 - Impact of immunomodulating medication on maternal Tdap vaccination-induced antibodies in infants
AU - Wieringa, Jantien W.
AU - Esser, Mirjam J.
AU - PETIT study
AU - Den Hartog, Gerco
AU - Nicolaie, M. Alina
AU - Rövekamp, Lyanne W.
AU - Rijntjes-Jacobs, Esther G.J.
AU - Van Beek, Ron H.T.
AU - Tramper-Stranders, Gerdien A.
AU - Kuijer, Marjan
AU - Immink, Maarten M.
AU - Van Der Maas, Nicoline A.T.
AU - Rots, Nynke Y.
AU - Driessen, Gertjan J.A.
AU - Van Achterberg, Hannie
AU - Van Den Akker, Eline S.A.
AU - Van Den Akker, Thomas
AU - Van Den Berg-Zuiddam, Denise
AU - Bloemenkamp, Kitty W.M.
AU - Van Dalen-Vink, Ilka H.
AU - Demmers, Judith
AU - Dijkman, Anneke
AU - Dik, Willem A.
AU - Dubbink-Verheij, Gerdina H.
AU - Van Dunné, Frederique M.
AU - Van Eijk, Rachel
AU - Esser, Mirjam J.
AU - Ganzevoort, Wessel
AU - El Ghabzouri, Hayat
AU - De Haan-Jibbink, Jiska M.
AU - Hajenius, Petra J.
AU - Van Houten, Marlies A.
AU - De Jong, Lenny
AU - Harzing, Bas
AU - Hermes, Wietske
AU - Heuts-Van De Kragt, Ingrid
AU - Hirdes, Meike M.C.
AU - Mulders, Annemarie G.M.G.J.
AU - Nagtzaam, Nicole M.A.
AU - Noordzij, Jeroen G.
AU - Simons, Sinno H.P.
AU - Sol, Jeanine J.
AU - Stas, Helene G.
AU - Van Veen, Mirjam
AU - Vermeulen, Marijn J.
AU - Vermont, Clementien L.
AU - Versendaal, Hans J.
AU - Van Vliet, Nanda S.M.
AU - Van Wering, Herbert M.
AU - Wijnberger, Lia D.E.
AU - Van Der Woude, C. Janneke
AU - van Sluijs, Sandra
AU - Binkhorst, Joke
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation. All rights reserved.
PY - 2025/6
Y1 - 2025/6
N2 - Background and Aims:Current international guidelines on inflammatory bowel disease (IBD) advise to continue immunomodulating medication during pregnancy. Data on the effect of this medication on maternal Tdap (Tetanus-Diphtheria-acellular pertussis) vaccination and transfer of antibodies to the infant are scarce. Methods:Pregnant women with IBD receiving various immunomodulating medications and their infants were prospectively recruited in the Pregnancy Exposure to TNF alpha inhibitors and Immunological effect (PETIT) study cohort from 16 hospitals in the Netherlands between December 2018 and March 2023. All women were offered maternal Tdap vaccination according to the Dutch National Immunization Program. IgG concentrations against all Tdap components were measured at birth (maternal and cord blood) and at 2 months of age in the infant, preceding active immunization. We compared geometrical mean concentrations (GMCs) in IBD mother-infant pairs with healthy control mother-infant pairs. Results: Geometrical mean concentrations of antibodies against all Tdap components were significantly higher in 135 maternally vaccinated mothers and their infants compared with 25 unvaccinated IBD women-infant pairs treated with immunomodulating medication during pregnancy, at all timepoints. However, GMC against pertactin (PRN) was significantly lower in vaccinated IBD mother-infant pairs compared to healthy vaccinated control mother-infant pairs, particularly in mothers treated with anti-tumor necrosis factor alpha and their infants. Conclusions: Maternal Tdap vaccination in women with IBD receiving immunomodulating medication during pregnancy results in significantly higher Tdap-antibody concentrations in their infants compared to infants of unvaccinated IBD mothers, although GMC was lower for PRN compared to healthy controls. These results support current recommendations to advise maternal Tdap vaccination in pregnant women receiving immunomodulating medication.
AB - Background and Aims:Current international guidelines on inflammatory bowel disease (IBD) advise to continue immunomodulating medication during pregnancy. Data on the effect of this medication on maternal Tdap (Tetanus-Diphtheria-acellular pertussis) vaccination and transfer of antibodies to the infant are scarce. Methods:Pregnant women with IBD receiving various immunomodulating medications and their infants were prospectively recruited in the Pregnancy Exposure to TNF alpha inhibitors and Immunological effect (PETIT) study cohort from 16 hospitals in the Netherlands between December 2018 and March 2023. All women were offered maternal Tdap vaccination according to the Dutch National Immunization Program. IgG concentrations against all Tdap components were measured at birth (maternal and cord blood) and at 2 months of age in the infant, preceding active immunization. We compared geometrical mean concentrations (GMCs) in IBD mother-infant pairs with healthy control mother-infant pairs. Results: Geometrical mean concentrations of antibodies against all Tdap components were significantly higher in 135 maternally vaccinated mothers and their infants compared with 25 unvaccinated IBD women-infant pairs treated with immunomodulating medication during pregnancy, at all timepoints. However, GMC against pertactin (PRN) was significantly lower in vaccinated IBD mother-infant pairs compared to healthy vaccinated control mother-infant pairs, particularly in mothers treated with anti-tumor necrosis factor alpha and their infants. Conclusions: Maternal Tdap vaccination in women with IBD receiving immunomodulating medication during pregnancy results in significantly higher Tdap-antibody concentrations in their infants compared to infants of unvaccinated IBD mothers, although GMC was lower for PRN compared to healthy controls. These results support current recommendations to advise maternal Tdap vaccination in pregnant women receiving immunomodulating medication.
UR - https://www.scopus.com/pages/publications/105009849455
U2 - 10.1093/ecco-jcc/jjaf090
DO - 10.1093/ecco-jcc/jjaf090
M3 - Article
C2 - 40452230
AN - SCOPUS:105009849455
SN - 1873-9946
VL - 19
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
IS - 6
M1 - jjaf090
ER -
SDG 3 Good Health and Well-being